TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment ...

Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions ...

Maki, PhD, explains that OPTION-VMS provided reassuring news about the safety of fezolinetant (Veozah): No new or emerging ...

JoAnn Pinkerton, MD: Elinzanetant is a dual neurokinin receptor inhibitor. It's an NK1 and NK3 receptor antagonist, and what ...

OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and ...

Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across ...

Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...

Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those ...

Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...

Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...

CBT is an evidence-based, nonhormonal option endorsed by the National Institutes of Health and The Menopause Society for ...

Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and ...